Dishman Carbogen Amcis peers

Companies like Dishman Carbogen Amcislatest year

Market cap and P/E at the last close; sales growth is the latest quarter on the same quarter a year before; ROE for the latest financial year.

Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

DCAL₹148.86

Dishman Carbogen Amcis Limited

· Pharma & Health
₹ CrorePeersHIKALSOLARAPANACEABIOINDSWFTLABSAIPARENTINDOCOSMSPHARMAWINDLASMcap ₹2,334 Cr
Comp Set
In ₹ Crore except Per Share
Latest Annual
DCAL
FY26
HIKAL
FY26
SOLARA
FY26
PANACEABIO
FY26
Peer
Average
Valuation — at last close
P/E23.93×————
P/B◆ 0.35×2.08×2.32×2.42×2.27× -85%
EV/EBITDA7.25×14.35×18.87×◆ -420.68×-129.15× +106%
Market Cap₹2,334 Cr₹2,496 Cr₹2,910 Cr₹2,017 Cr₹2,474 Cr -6%
Growth
Revenue CAGR 3Y6.71%-5.40%-1.76%◆ 11.63%1.49% +350%
Revenue CAGR 5Y◆ 8.93%-0.09%-3.27%0.47%-0.96% +1027%
Revenue YoY (latest Q)-4.29%5.89%◆ 33.11%19.72%19.57% -122%
Net Income YoY (latest Q)-347.24%66.96%◆ 381.78%-44.44%134.77% -358%
Profitability
EBITDA Margin◆ 19.29%12.87%13.64%-0.73%8.59% +124%
Net Income Margin◆ 3.32%-2.85%-0.54%-1.12%-1.50% +321%
Return on Common Equity◆ 1.56%-3.97%-0.63%-0.64%-1.75% +189%
Return on Capital Employed2.57%3.30%◆ 6.39%-4.11%1.86% +38%
Return on Assets◆ 0.89%-1.99%-0.32%-0.56%-0.96% +193%
Credit & Quality
Total Debt/Equity0.42×0.57×0.53×◆ 0.03×0.38× +12%
Interest Coverage◆ 1.30×0.91×0.92×-6.23×-1.47× +189%
Scale — latest FY
Revenue / Total Income₹2,932 Cr₹1,713 Cr₹1,369 Cr₹640 Cr₹1,240 Cr +136%
Net Income₹97.5 Cr−₹48.8 Cr−₹7.4 Cr−₹7.2 Cr−₹21.1 Cr +561%
Total Assets₹11,923 Cr₹2,365 Cr₹2,333 Cr₹1,262 Cr₹1,987 Cr +500%
EPS₹6.22₹-3.96₹-1.68₹-0.88₹-2.17 +386%
Book Value per Share₹425.82₹97.07₹281.48₹136.19₹171.58 +148%
◆ best value in the comp set per metric · Δ = subject vs average of the other companies.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.